MB101

About Modiblast Pharma

Modiblast Pharma, founded in 2018 and based in Munich, is a preclinical-stage biotech pioneering an in vivo cell reprogramming platform for oncology. The company's core technology, following a 'Trojan horse' motif, seeks to reprogram cancer cells to stimulate innate and adaptive immunity, with the goal of creating a backbone maintenance therapy to extend remission. Currently raising its seed round, Modiblast is progressing its lead candidate, MB101, a fixed-dose combination for AML, toward a first-in-human trial. The long-term vision includes developing a self-administerable, at-home therapy to improve patient quality of life.

Therapeutic Areas